<DOC>
	<DOCNO>NCT00740467</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine , busulfan , cyclophosphamide , together antithymocyte globulin donor stem cell transplant help stop growth cancer abnormal cell . Giving chemotherapy transplant also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well stem cell transplant work treat patient hematological cancer disorder .</brief_summary>
	<brief_title>Stem Cell Transplant Treating Patients With Hematological Cancer Other Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate incidence graft acceptance patient hematological disorder treat combined immunosuppression HLA-haploidentical hematopoietic stem cell transplantation . Secondary - Evaluate efficacy regimen patient . - Evaluate toxicity regimen patient . - Assess survival patient treat regimen . OUTLINE : This multicenter study . - Reduced-intensity conditioning : Patients receive fludarabine phosphate IV day -6 -1 , busulfan IV day -6 -5 , anti-thymocyte globulin IV day -4 -1 . - Transplantation : Patients undergo transplantation donor hematopoietic stem cell day 0 . Patients also receive cyclophosphamide IV day 3 filgrastim ( G-CSF ) begin day 4 continue blood count recover . - Immunosuppression : Patients receive cyclosporine IV begin day -2 continue 6 month mycophenolate mofetil 4 time day day 4-84 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow hematological cancer poor prognosis : Acute myeloid leukemia meeting 1 follow criterion : Third complete remission ( CR3 ) beyond CR2 early bone marrow relapse ( &lt; 24 month ) Refractory disease ≥ 2 chemotherapy course induction therapy Acute lymphoblastic leukemia meeting 1 follow criterion : CR3 ≥ 1 bone marrow relapse CR2 early bone marrow relapse ( currently within 6 month stop maintenance therapy ) Chronic myelogenous leukemia meeting follow criterion : Accelerated phase Second chronic phase No treatment option Multiple myeloma meeting follow criterion : Failed conventional therapy ( include autologous hematopoietic stem cell transplantation ) No treatment alternative Chronic lymphocytic leukemia meeting follow criterion : Failed conventional therapy No treatment alternative Hodgkin lymphoma meeting follow criterion : Failed conventional therapy No treatment alternative NonHodgkin lymphoma meeting follow criterion : Failed conventional therapy No treatment alternative Not eligible standard myeloablative allograft due increase toxicity Healthy relate donor available meeting follow criterion : Brother , sister , father , mother , cousin , uncle , aunt At least identical HLA haplotype Identical genotype 1 haplotype ( term HLAA , B , C , DR ) Different ≤ 4 allele haplotype No HLAidentical intra extrafamilial donor cord blood available within next 3 month PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Not pregnant nursing Fertile patient must use effective contraception No contraindication allogeneic transplantation , include follow : Cardiac systolic ejection fraction &lt; 40 % DLCO level limit use fludarabine Creatinine clearance &lt; 30 mL/min Transaminases and/or bilirubin &gt; 3 time upper limit normal ( unless due Gilbert disease cancer ) HIV seropositivity Human Tcell lymphotrophic virus type 1 seropositivity Uncontrolled bacterial , viral , fungal infection No contraindication study drug No prior concurrent psychiatric illness No cancer past 5 year except basal cell skin cancer carcinoma situ cervix No concurrent serious , uncontrolled condition No patient deprive liberty subject legal protection PRIOR CONCURRENT THERAPY : No participation study allograft past month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade I lymphomatoid granulomatosis</keyword>
	<keyword>recurrent grade II lymphomatoid granulomatosis</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>